Wall Street analyst estimates for Lunai Bioworks Inc. (LNAI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Valuation Ratios
| Price / Book | -0.71 |
| EV / EBITDA | -0.07 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $391416 | 0 | 0 | 0 | $129094 |
| Gross Profit | -$391416 | 0 | 0 | 0 | -$129094 |
| Research & Development | $15.5M | $8.4M | $4.2M | $2.7M | $537428 |
| Selling, General & Admin | $7.5M | $14.3M | $15.3M | $24.6M | $17.9M |
| Operating Expenses | $23.0M | $116.1M | $38.6M | $81.6M | $18.4M |
| Operating Income | -$23.4M | -$116.1M | -$38.6M | -$81.6M | -$18.5M |
| EBITDA | -$26.1M | -$112.9M | -$38.9M | -$85.9M | -$177.2M |
| Interest Expense | $379608 | $372844 | $706964 | $2.4M | $725684 |
| Pre-tax Income | -$26.8M | -$113.4M | -$39.7M | -$88.4M | -$178.0M |
| Income Tax | -$125276 | $34 | 0 | 0 | 0 |
| Net Income | -$26.7M | -$113.4M | -$39.7M | -$88.4M | -$178.0M |
| EPS | $-45.36 | $-172.80 | $-56.80 | $-72.80 | $-86.24 |
| EPS (Diluted) | $-45.36 | $-172.80 | $-56.80 | $-72.80 | $-86.24 |
| Shares Outstanding (Diluted) | $589591 | $656600 | $703317 | $1.2M | $2.1M |
Price
| Price | $2.17 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADAP · ANL · APLM · BLRX · ERNA · GOVX · ICU
Explore sector: Healthcare · Biotechnology
More sections of LNAI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks